John Crowley, Amicus CEO (via YouTube)
January 11, 2022 06:49 AM ESTUpdated 07:00 AM
Bioregnum
Cell/Gene Tx

Am­i­cus gets hit with an 'un­ex­pect­ed' set­back on a gene ther­a­py tapped to lead $600M SPAC spin­out

Am­i­cus has tak­en the axe and chopped a gene ther­a­py for Bat­ten dis­ease out of the pipeline af­ter an “un­ex­pect­ed” set­back in the clin­ic. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times